Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Sep 22;211(10):1925–1935. doi: 10.1084/jem.20140131

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2014 Boyd et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

PMC Copyright notice

Figure 3. — Mobilization treatment displaces normal and leukemic human repopulating cells from the xenograft BM niche, facilitating competitive homing by subsequent HSPC transplants. (A) Experimental design to investigate the effects of mobilization treatment on established human CB grafts. (B) Human WBC distribution 1 h after final treatment of CB xenografts with mobilization agents or vehicle (saline n = 6, mobilization n = 5). **, P < 0.01, unpaired Student’s t test (bar graph). Each data point represents an individual mouse and slopes were significantly different (scatter plot; linear regression P < 0.05). (C) Representative flow cytometry plots show that human CD45⁺ cells can be detected in the spleens of xenografted mice 1 h after treatment with either vehicle or mobilization agents (top row). However, only splenic populations from mobilized mice possess repopulating activity, as measured by intrafemoral transplantation into secondary recipients (bottom row). Plots are representative of serial transplantation performed from spleens of 18 xenografted primary mice. (D) Experimental design to investigate the effects of mobilization agents on established human AML grafts. (E) Tissue distribution of human leukemic CD45⁺ cells 1 h after final treatment with mobilization agents or vehicle. Each data point represents an individual mouse. Slopes were significantly different, linear regression P < 0.05 (PB) and P < 0.0005 (spleen). (F) Experimental design to test whether mobilization of established human leukemic grafts can facilitate competitive niche replacement by subsequent HSPC transplants (CB Lin⁻ cells). (G) Relative frequency of DiO-labeled CB Lin⁻ cells homed to the BM of AML-engrafted mice after mobilization or vehicle treatment (n = 3 each). ***, P < 0.005, unpaired Student’s t test.